Status:
UNKNOWN
Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Shandong Cancer Hospital and Institute
Collaborating Sponsors:
Peking University Cancer Hospital & Institute
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to observe quality of life and treatment side effects in patients with advanced non small cell lung cancer (NSCLC) receive chemotherapy and Yangzhengxiaoji capsule.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Histology and/or cytology confirmed stage Ⅳ NSCLC patients;
- With at least one measurable solid tumor (RECIST standard version 1.1): tumor \>=10 mm in diameter on CT or MRI images, or lymph node \>=15 mm in diameter on CT or MRI images;
- Eastern Cooperative Oncology Group(ECOG) score 0-1, expectant survival \> 3 months;
- Age: 18-70 years;
- Normal organ function:
- Bone marrow: neutrophils (ANC) count\>=1.5×10\^9/L, Platelets count\>=100×10\^9/L, hemoglobin\>=90g/L；Renal function, serum creatinine\<=1.5 mg/dl, and/or creatinine clearance or\>=60 ml/min; Liver function: total serum bilirubin levels \<= 1.5 times the upper limit of normal (ULN), serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT)\<=2.5 times the ULN, if abnormal liver function caused by the underlying malignancy, the AST and ALT \>=5 times ULN;
- For patients with brain metastases, bone metastases or pleural effusion, systemic chemotherapy is proposed after the effective local treatment to control symptoms;
- Informed consent.
- Exclusion criteria:
- Clinically significant hepatic dysfunction: AST or ALT \> 2.5 times the ULN, total serum bilirubin levels \> 1.5 times the ULN; clinically significant renal insufficiency: serum creatinine \> 1.5 times the ULN;
- Severe heart disease: New York Heart Association class Ⅲ-IV class of heart failure, unstable angina, myocardial infarction, coronary revascularization six months before randomization;
- Spleen resection or combined with other severe hematopoietic system diseases;
- Uncontrolled diabetes, hypertension (above 180/120mmHg), infection or severe gastrointestinal ulcers;
- History or present with other cancer, except for non melanoma skin cancer, cervical cancer in situ and other cured cancer for at least 5 years;
- Mental illness, without legal capacity or limited capacity;
- Pregnancy, lactation or patients with pregnancy plan;
- Participated in other clinical trail in the past 1 months or participating in other trail now;
- Other unsuitable condition decided by the investigator.
Exclusion
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
520 Patients enrolled
Trial Details
Trial ID
NCT02195453
Start Date
August 1 2014
End Date
December 1 2016
Last Update
July 21 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.